Back to today’s briefing

Story perspectives

Promising Nivolumab Trial Reshapes Head and Neck Cancer Care

6/9/2025

35 6

Summary

Adkins Advances Cancer Care

The phase 3 NIVOPOSTOP trial in Europe has shown promising results for nivolumab as an adjuvant therapy in treating locally advanced head and neck squamous cell carcinoma. With improved patient outcomes when paired with standard treatments, Douglas R. Adkins believes these findings could reshape care practices, offering hope for better strategies in this challenging battle against cancer.

Summary

Legend Biotech's Breakthrough

A groundbreaking CAR-T immunotherapy, Carvykti, from Legend Biotech, is making waves in the fight against advanced multiple myeloma. In a trial involving 97 patients, nearly one-third celebrated five years of remission without additional treatment. Unveiled at the ASCO conference, these results ignite hope for a potential cure for this once-incurable blood cancer.

1 of 2

Adkins Advances Cancer Care

The phase 3 NIVOPOSTOP trial in Europe has shown promising results for nivolumab as an adjuvant therapy in treating locally advanced head and neck squamous cell carcinoma. With improved patient outcomes when paired with standard treatments, Douglas R. Adkins believes these findings could reshape care practices, offering hope for better strategies in this challenging battle against cancer.

1 / 2